Please login to the form below

Not currently logged in
Email:
Password:

checkpoint inhibitor

This page shows the latest checkpoint inhibitor news and features for those working in and with pharma, biotech and healthcare.

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

The hope for the Opdivo/Yervoy combo is to reclaim significant growth for BMS’ star PD-1 checkpoint inhibitor – in its third-quarter results, the company revealed that Opdivo grew just

Latest news

More from news
Approximately 4 fully matching, plus 160 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... 50%. The true figure for patients treated with checkpoint inhibitor monotherapy achieving durable and meaningful clinical responses is in fact nearer 20%.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but there remains room for growth in the market via new IO agents. ... t the only oral JAK inhibitor developer with its eye on that

  • Is China ready for a pharmaceutical gold rush?

    The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... In light of recent clinical data, Keytruda is widely regarded as the better of the two checkpoint inhibitors in

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    There’s little doubt immunotherapy is leading the charge at the moment, headed by checkpoint inhibitors that target receptors that inhibit the patient’s own immune response, as well as ... Meanwhile, despite the mixed results for checkpoint inhibitor

  • Deal Watch January 2017 Deal Watch January 2017

    But it was not all inward traffic with the company announcing a global collaboration with Ovid to jointly develop and commercialise Takeda's selective CH24H inhibitor TAK-935 for the treatment ... 3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics